Antigens and granularity of blood monocytes in relation to inflammatory markers and lipids in postmenopausal women

Boudjeltia, Karim Zouaoui; Gregoir, C.; Guillaume, M.; Remacle, Claude; Piro, P.; Garbar, Christian; Ducobu, Jean; Moguilevsky, Nicole; Vanhaeverbeek, Michel; Delrée, P.; Brohée, Dany

doi:10.1016/j.maturitas.2005.12.009

Cited by 4 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Simulset IMK Plus kit was used, and the expression of the relevant antigens (CD14, HLA-DR) by monocytes was studied using CellQuest software. CD14 or HLA-DR fluorescence intensities of the monocytes were arbitrarily expressed as a ratio of the median value (1 to 10 000 log 10 scale) of the monocytes to the median intensity of the lymphocytes used as internal calibrators for phycoerythrine (PE) fluorescence (bright CD8 subset) and for fluoroisothiocyanate (FITC) fluorescence (CD4 subset) (Zouaoui Boudjeltia et al 2006a). We used the following couples of monoclonal antibodies: CD14-CD62L, CD4-CD8, CD3-HLA-DR (Becton Dickinson).…”

Section: Flow Cytometrymentioning

confidence: 99%

“…The euglobulin clot lysis time (ECLT), which is the most common test used to estimate plasma fibrinolytic capacity, represents the balance between t-PA and PAI-1 activities (Zouaoui Boudjeltia et al 2006a). ECLT of fresh plasma was measured on the same day as other parameters by a method described elsewhere (Zouaoui Boudjeltia et al 2002).…”

Section: Plasma Fibrinolytic Capacitymentioning

confidence: 99%

“…In postmenopausal women, we have previously observed that fibrinogen, high-sensitivity (hs)-CRP, and fibrinogen levels were correlated with a decrease in HLA-DR expression by monocytes, reflecting reduced antigenpresenting capacity (Zouaoui Boudjeltia et al 2006a). We also observed that a decreased expression of CD14 antigen (hallmark of a maturation process) was associated with LDL concentrations (Zouaoui Boudjeltia et al 2006a). Moreover, monocytes are modulators of fibrinolysis (Funayama et al 1997;Zouaoui Boudjeltia et al 2006b).…”

Section: Introductionmentioning

confidence: 98%

“…Circulating monocytes from menopausal women spontaneously up-regulate the expression and secretion in culture of the proinflammatory cytokines, interleukin (IL)-1 and tumour necrosis factor (TNF)-a, in contrast to that of monocytes from premenopausal women (Pacifici et al 1991). In postmenopausal women, we have previously observed that fibrinogen, high-sensitivity (hs)-CRP, and fibrinogen levels were correlated with a decrease in HLA-DR expression by monocytes, reflecting reduced antigenpresenting capacity (Zouaoui Boudjeltia et al 2006a). We also observed that a decreased expression of CD14 antigen (hallmark of a maturation process) was associated with LDL concentrations (Zouaoui Boudjeltia et al 2006a).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effects of raloxifene treatment on the phenotype of blood monocytes

Boudjeltia

Durez

Oberweis

et al. 2010

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

Raloxifene (RLX), a selective oestrogen receptor modulator, has oestrogen-agonist effects on bone, lipoproteins, and homocysteine and oestrogen-antagonist activity in the breast and uterus, positioning it as a potential drug for long-term prevention of coronary heart disease in postmenopausal women. To further evaluate its influence on cardiovascular risk factors, we studied the effects of 60 mg/day RLX on serum lipid levels, inflammatory (high-sensitivity C-reactive protein, and coagulation (fibrinogen) markers, monocytes, and fibrinolysis in 15 healthy postmenopausal women. Markers were measured at baseline, after 1 month without treatment, and after 3 months of treatment. Fibrinolysis was evaluated using the euglobulin clot lysis time (ECLT) determined with a new semiautomatic optical method. Monocyte phenotype was determined by measurement of the expression of the antigens CD14, HLA-DR, and CD62-L using flow cytometry. After 3 months of RLX treatment, we observed a decrease in total cholesterol (p = 0.002), in low-density lipoprotein cholesterol (p <0.001), and in lipoprotein A (p = 0.01). Fibrinogen (p = 0.002) decreased significantly, and high-sensitivity C-reactive protein had a tendency to decrease, but this did not reach statistical significance (p = 0.06). RLX treatment had no effect on ECLT (p = 0.223) or on white blood cell, lymphocyte, and total monocyte counts (p = 0.313). Monocyte expression of HLA-DR, CD14, and CD62-L was not modified by the treatment. In conclusion, we confirm that RLX has beneficial short-term effects on levels of lipids and inflammatory markers, with no effect on fibrinolysis or monocyte phenotype.

show abstract

Section: Flow Cytometrymentioning

confidence: 99%

Section: Plasma Fibrinolytic Capacitymentioning

confidence: 99%